Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Non-Current Liabilities (2024 - 2025)

Historic Other Non-Current Liabilities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $2.9 million.

  • Prelude Therapeutics' Other Non-Current Liabilities fell 789.72% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 789.72%. This contributed to the annual value of $3.1 million for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Other Non-Current Liabilities stood at $2.9 million for Q3 2025, which was down 789.72% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Other Non-Current Liabilities registered a high of $3.3 million during Q1 2024, and its lowest value of $2.9 million during Q3 2025.